Non-small cell lung cancer with MET amplification: review of epidemiology, associated disease characteristics, testing procedures, burden, and treatments.
| العنوان: | Non-small cell lung cancer with MET amplification: review of epidemiology, associated disease characteristics, testing procedures, burden, and treatments. |
|---|---|
| المؤلفون: | Yang M; North America Evidence and Value Development, North America Medical Affairs, EMD Serono, Inc., Rockland, MA, United States, an affiliate of Merck KGaA., Mandal E; Evidence and Access, OPEN Health, Parsippany, NJ, United States., Liu FX; North America Evidence and Value Development, North America Medical Affairs, EMD Serono, Inc., Rockland, MA, United States, an affiliate of Merck KGaA., O'Hara RM Jr; North America Evidence and Value Development, North America Medical Affairs, EMD Serono, Inc., Rockland, MA, United States, an affiliate of Merck KGaA., Lesher B; Evidence and Access, OPEN Health, Parsippany, NJ, United States., Sanborn RE; Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, United States. |
| المصدر: | Frontiers in oncology [Front Oncol] 2024 Jan 11; Vol. 13, pp. 1241402. Date of Electronic Publication: 2024 Jan 11 (Print Publication: 2023). |
| نوع المنشور: | Systematic Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Original Publication: [Lausanne : Frontiers Research Foundation] |
| مستخلص: | Introduction: Mesenchymal-epidermal transition factor gene amplification ( MET amp) is being investigated as a therapeutic target in advanced non-small cell lung cancer (NSCLC). We reviewed the epidemiology and disease characteristics associated with primary and secondary MET amp, as well as the testing procedures used to identify MET amp, in advanced NSCLC. Economic and humanistic burdens, and the practice patterns and treatments under investigation for MET amp were also examined. Methods: Embase and Medline (via ProQuest), ClinicalTrials.gov, and Cochrane Controlled Register of Trials (2015-2022) were systematically searched. Conference abstracts were searched via Embase and conference proceedings websites (2020-2022). The review focused on evidence from the United States; global evidence was included for identified evidence gaps. Results: The median rate of primary MET amp in NSCLC across the references was 4.8% (n=4 studies) and of secondary MET amp (epidermal growth factor receptor [ EGFR ]-mutant NSCLC) was 15% (n=10). Next-generation sequencing (NGS; n=12) and/or fluorescence in situ hybridization (FISH; n=11) were most frequently used in real-world studies and FISH testing most frequently used in clinical trials (n=9/10). MET amp definitions varied among clinical trials using ISH/FISH testing (MET to chromosome 7 centromere ratio of ≥1.8 to ≥3.0; or gene copy number [GCN] ≥5 to ≥10) and among trials using NGS (tissue testing: GCN ≥6; liquid biopsy: MET copy number ≥2.1 to >5). Limited to no data were identified on the economic and humanistic burdens, and real-world treatment of MET amp NSCLC. Promising preliminary results from trials enrolling patients with EGFR -mutated, MET amp advanced NSCLC progressing on an EGFR-tyrosine kinase inhibitor (TKI) were observed with MET-TKIs (i.e., tepotinib, savolitinib, and capmatinib) in combination with EGFR-TKIs (i.e., gefitinib and osimertinib). For metastatic NSCLC and high-level MET amp, monotherapy with capmatinib, crizotinib, and tepotinib are recommended in the 2022 published NSCLC NCCN Guidelines. Conclusion: Primary MET amp occurs in approximately 5% of NSCLC cases, and secondary MET amp in approximately 15% of cases previously treated with an EGFR inhibitor. Variability in testing methods (including ISH/FISH and NGS) and definitions were observed. Several treatments are promising in treating MET amp NSCLC. Additional studies evaluating the clinical, economic, and humanistic burdens are needed. Competing Interests: Authors MY, FL, and RH were employed by the company EMD Serono, Inc., Rockland, MA, USA, an affiliate of Merck KGaA, at the time of the study. Authors EM and BL were employed by the company OPEN Health at the time of this study, which was the recipient of consulting fees from EMD Serono, Inc., Rockland, MA, USA, an affiliate of Merck KGaA. Author RS received honoraria from AstraZeneca, and Amgen; attended advisory boards and provided consulting for AstraZeneca, EMD Serono, Inc., Rockland, MA, USA, an affiliate of Merck KGaA, Daiichi Sankyo, Lilly, Janssen Oncology, Macrogenics, Sanofi/Aventis, Regeneron, Mirati Therapeutics, and GlaxoSmithKline; received research funding from Merck, AstraZeneca Investigator-sponsored trials, and BMS Institution research funding. (Copyright © 2024 Yang, Mandal, Liu, O’Hara, Lesher and Sanborn.) |
| References: | Biochim Biophys Acta. 2015 Dec;1856(2):189-210. (PMID: 26297204) Clin Lung Cancer. 2020 May;21(3):e191-e204. (PMID: 31859066) Ann Oncol. 2018 Oct 1;29(Suppl 4):iv192-iv237. (PMID: 30285222) J Thorac Oncol. 2021 Jun;16(6):1017-1029. (PMID: 33676017) Clin Lung Cancer. 2021 Jul;22(4):e512-e518. (PMID: 33288441) Thorac Cancer. 2022 Jun;13(11):1619-1630. (PMID: 35437920) JTO Clin Res Rep. 2021 Oct 08;2(11):100239. (PMID: 34766065) Lung Cancer. 2021 Mar;153:126-133. (PMID: 33486418) Lung Cancer. 2020 Aug;146:165-173. (PMID: 32540560) Clin Lung Cancer. 2021 Jul;22(4):e519-e527. (PMID: 33414052) Clin Respir J. 2018 Apr;12(4):1416-1423. (PMID: 28756651) Cancer. 2016 Mar 1;122(5):766-72. (PMID: 26695526) Ann Transl Med. 2017 Jan;5(1):4. (PMID: 28164089) Oncotarget. 2018 Feb 7;9(16):12959-12970. (PMID: 29560123) Jpn J Clin Oncol. 2019 Aug 1;49(8):755-761. (PMID: 31329925) Clin Cancer Res. 2018 Mar 1;24(5):1038-1047. (PMID: 29217530) Oncologist. 2019 Aug;24(8):1022-1026. (PMID: 31023862) Lancet Respir Med. 2020 Nov;8(11):1132-1143. (PMID: 32479794) Oncol Res Treat. 2017;40(4):198-202. (PMID: 28324883) Clin Cancer Res. 2021 Nov 1;27(21):5781-5792. (PMID: 34426443) J Hematol Oncol. 2019 Jun 21;12(1):63. (PMID: 31227004) Cell Rep Med. 2023 Nov 21;4(11):101280. (PMID: 37944528) Clin Cancer Res. 2021 May 15;27(10):2899-2909. (PMID: 33685866) Int J Mol Sci. 2022 Nov 11;23(22):. (PMID: 36430388) Cancer Discov. 2018 Jun;8(6):714-729. (PMID: 29650534) Front Oncol. 2021 Oct 01;11:722039. (PMID: 34660287) Eur J Cancer. 2017 Dec;87:131-139. (PMID: 29145039) ESMO Open. 2021 Dec;6(6):100319. (PMID: 34837746) J Med Econ. 2022 Jan-Dec;25(1):457-468. (PMID: 35289703) Clin Cancer Res. 2016 Dec 15;22(24):6010-6020. (PMID: 27281561) J Transl Med. 2019 Feb 21;17(1):52. (PMID: 30791921) N Engl J Med. 2020 Sep 3;383(10):944-957. (PMID: 32877583) J Clin Oncol. 2018 Mar 20;36(9):841-849. (PMID: 28841389) Exp Hematol Oncol. 2021 Nov 10;10(1):52. (PMID: 34758872) Clin Cancer Res. 2018 Dec 15;24(24):6195-6203. (PMID: 30228210) Cancers (Basel). 2021 Jun 21;13(12):. (PMID: 34205733) J Thorac Oncol. 2016 Jul;11(7):e83-5. (PMID: 26988570) Nat Rev Clin Oncol. 2020 Sep;17(9):569-587. (PMID: 32514147) Cancers (Basel). 2022 May 14;14(10):. (PMID: 35626038) J Thorac Oncol. 2021 May;16(5):850-859. (PMID: 33545388) Mol Oncol. 2021 Feb;15(2):350-363. (PMID: 33236532) Cancers (Basel). 2023 Jan 18;15(3):. (PMID: 36765572) Lancet Oncol. 2020 Mar;21(3):373-386. (PMID: 32027846) J Thorac Oncol. 2019 Sep;14(9):1666-1671. (PMID: 31228623) Lung Cancer. 2015 Dec;90(3):381-7. (PMID: 26791796) Cancers (Basel). 2021 Oct 07;13(19):. (PMID: 34638507) Clin Cancer Res. 2019 Dec 15;25(24):7312-7319. (PMID: 31416808) Cell Rep Med. 2020 Apr 21;1(1):. (PMID: 32483558) JAMA Oncol. 2021 Dec 01;7(12):1824-1832. (PMID: 34673888) J Natl Compr Canc Netw. 2022 May;20(5):497-530. (PMID: 35545176) Ann Oncol. 2020 Dec;31(12):1725-1733. (PMID: 33007380) Cancer Treat Res Commun. 2019;18:100113. (PMID: 30472556) Mod Pathol. 2019 May;32(5):627-638. (PMID: 30459450) Oncotarget. 2021 Oct 26;12(22):2273-2282. (PMID: 34733418) JCO Precis Oncol. 2019 Dec;3:1-9. (PMID: 35100695) Clin Lung Cancer. 2017 Mar;18(2):213-219.e2. (PMID: 28322191) Clin Lung Cancer. 2019 Jan;20(1):30-36.e3. (PMID: 30279110) J Cancer Res Ther. 2015 Aug;11 Suppl 1:C63-7. (PMID: 26323927) Exp Mol Pathol. 2021 Feb;118:104572. (PMID: 33189723) Invest New Drugs. 2021 Apr;39(2):477-487. (PMID: 33052556) J Thorac Oncol. 2018 Mar;13(3):323-358. (PMID: 29396253) Lung Cancer. 2020 Nov;149:17-22. (PMID: 32949827) Thorac Cancer. 2017 Sep;8(5):417-422. (PMID: 28590585) Oncotarget. 2017 Oct 9;8(62):105103-105114. (PMID: 29285237) Oncologist. 2022 Oct 1;27(10):839-848. (PMID: 35598205) Clin Cancer Res. 2020 Jun 1;26(11):2654-2663. (PMID: 31911548) Cancer Discov. 2016 Oct;6(10):1118-1133. (PMID: 27432227) N Engl J Med. 2021 Jun 24;384(25):2382-2393. (PMID: 34161704) Cancer. 2018 Sep 1;124(17):3586-3595. (PMID: 30120912) Science. 2007 May 18;316(5827):1039-43. (PMID: 17463250) Oncotarget. 2021 Aug 31;12(18):1802-1810. (PMID: 34504652) Thorac Cancer. 2022 Nov;13(21):3032-3041. (PMID: 36101520) Clin Lung Cancer. 2017 Nov;18(6):651-659. (PMID: 28479369) Oncotarget. 2018 Feb 08;9(17):13682-13693. (PMID: 29568386) Lung Cancer. 2021 Sep;159:96-106. (PMID: 34320421) J Clin Oncol. 2018 Nov 1;36(31):3101-3109. (PMID: 30156984) Front Oncol. 2021 Jun 24;11:649766. (PMID: 34249687) Mod Pathol. 2018 Feb;31(2):307-312. (PMID: 28914263) |
| فهرسة مساهمة: | Keywords: epidemiology; epithelial-mesenchymal transition; non-small cell lung carcinoma; systematic review; treatment outcome |
| تواريخ الأحداث: | Date Created: 20240126 Latest Revision: 20240128 |
| رمز التحديث: | 20240128 |
| مُعرف محوري في PubMed: | PMC10808753 |
| DOI: | 10.3389/fonc.2023.1241402 |
| PMID: | 38273845 |
| قاعدة البيانات: | MEDLINE |
كن أول من يترك تعليقا!